The emergence of antimicrobial resistance is a significant public health issue worldwide,
particularly for healthcare-associated infections caused by carbapenem-resistant gram …

Introduction: The emergence of multidrug-resistant bacterial pathogens has led to a global
public health emergency and novel therapeutic options and drug-delivery systems are …

ABSTRACT Cefiderocol (formerly S-649266) is a novel siderophore-conjugated
cephalosporin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram …

ABSTRACT Cefiderocol (CFDC; S-649266), a novel parenteral siderophore cephalosporin
conjugated with a catechol moiety, has a characteristic antibacterial spectrum with a potent …

Cefiderocol (CFDC),(formerly S‐649266), is a novel injectable siderophore cephalosporin
developed by Shionogi & Co., Ltd., with potent in vitro activity against Gram‐negative …

Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by
Shionogi & Co., Ltd., Japan. As with other β-lactam antibiotics, the principal antibacterial …

Abstract Cefiderocol, formerly S-649266, is a first in its class, an injectable siderophore
cephalosporin that combines a catechol-type siderophore and cephalosporin core with side …

Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a
“Trojan horse” active transport mechanism to enter bacteria and has proven in vitro activity …

Cefiderocol is a novel parenteral siderophore cephalosporin that shows potent efficacy
against various Gram-negative bacteria, including carbapenem-resistant strains, in vitro and …

Objective: This article reviews the available data on the chemistry, spectrum of activity,
pharmacokinetic and pharmacodynamic properties, clinical efficacy, and potential place in …